RECRUITINGOBSERVATIONAL
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
About This Trial
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.
Who May Be Eligible (Plain English)
Who May Qualify:
1. diagnosed by tissue sample (biopsy-confirmed) non-metastatic invasive breast cancer.
2. Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
3. If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
4. Be aged 18 years and over.
5. Have given written willing to sign a consent form to participate.
Who Should NOT Join This Trial:
1. Metastatic breast cancer at diagnosis.
2. Treatment with neoadjuvant endocrine therapy only.
3. Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Histologically confirmed non-metastatic invasive breast cancer.
2. Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
3. If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
4. Be aged 18 years and over.
5. Have given written informed consent to participate.
Exclusion Criteria:
1. Metastatic breast cancer at diagnosis.
2. Treatment with neoadjuvant endocrine therapy only.
3. Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
Locations (1)
Royal Marsden NHS Foundation Trust
London, United Kingdom